Outlook Therapeutics (OTLK) Revenue (2015 - 2025)

Outlook Therapeutics (OTLK) posted quarterly Revenue of -$91787.0 for Q3 2025, down 106.1% quarter-over-quarter from $1.5 million in Q2 2025.

Outlook Therapeutics (OTLK) Revenue (2015 - 2025) Analysis & Trends

Outlook Therapeutics (OTLK) has reported Revenue for 6 consecutive years, with -$91787.0 the latest figure, recorded in Q3 2025.

In Q3 2025, Revenue changed N/A year-over-year to -$91787.0; the TTM figure through Sep 2025 stood at $7.9 million (changed N/A YoY), while the FY2025 annual figure was $1.4 million, changed N/A from the prior year.
Revenue retreated to -$91787.0 in Q3 2025 per OTLK's latest filing, from $1.5 million in the prior quarter.
Across five years, Revenue topped out at $1.5 million in Q2 2025 and bottomed at -$91787.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.52 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.29 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	425.49 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	674.14 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.06 Bn
10	Outlook Therapeutics	93.64 Mn	82.40 Mn	-8,265.00	-

Download Data